Scopolamine patch interactions

Dexchlorpheniramine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Dextromethorphan; Diphenhydramine; Phenylephrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.

Dextromethorphan; Promethazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including promethazine. Dextromethorphan; Quinidine: Moderate The reduction in GI motility produced by scopolamine may increase the absorption of some drugs, including quinidine, resulting in increased anticholinergic effects.

Increased monitoring is advised in patients receiving this combination. Routine therapeutic monitoring should be continued when an antimuscarinic agent is prescribed with digoxin until the effects of combined use are known. Dihydrocodeine; Guaifenesin; Pseudoephedrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when dihydrocodeine is used concomitantly with an anticholinergic drug.

Dimenhydrinate: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Diphenhydramine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.

Diphenhydramine; Hydrocodone; Phenylephrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Diphenhydramine; Ibuprofen: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.

Diphenhydramine; Naproxen: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Diphenhydramine; Phenylephrine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Disopyramide: Moderate In addition to its electrophysiologic effects, disopyramide exhibits clinically significant anticholinergic properties. These can be additive with other anticholinergics.

Clinicians should be aware that urinary retention, particularly in males, and aggravation of glaucoma are realistic possibilities of using disopyramide with other anticholinergic agents. Donepezil: Moderate The therapeutic benefits of donepezil, a cholinesterase inhibitor, may be diminished during chronic co-administration with antimuscarinics or medications with potent anticholinergic activity.

When concurrent use is not avoidable, the patient should be monitored for cognitive decline and anticholinergic side effects. Clinicians should generally avoid multiple medications with anticholinergic activity in the patient with dementia. Some of the common selective antimuscarinic drugs for bladder problems, such as oxybutynin, darifenacin, trospium, fesoterodine, tolerodine, or solifenacin , do not routinely cause problems with medications used for dementia, but may cause anticholinergic side effects in some patients.

Atropine may be used to offset bradycardia in cholinesterase inhibitor overdose. Donepezil; Memantine: Moderate The adverse effects of anticholinergics, such as dry mouth, urinary hesitancy or blurred vision may be enhanced with use of memantine; dosage adjustments of the anticholinergic drug may be required when memantine is coadministered.

In addition, preliminary evidence indicates that chronic anticholinergic use in patients with Alzheimer's Disease may possibly have an adverse effect on cognitive function. Therefore, the effectiveness of drugs used in the treatment of Alzheimer's such as memantine, may be adversely affected by chronic antimuscarinic therapy. Moderate The therapeutic benefits of donepezil, a cholinesterase inhibitor, may be diminished during chronic co-administration with antimuscarinics or medications with potent anticholinergic activity.

Doxylamine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Doxylamine; Pyridoxine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Dronabinol: Moderate Use caution if coadministration of dronabinol with anticholinergics is necessary.

Concurrent use of dronabinol, THC with anticholinergics may result in additive drowsiness, hypertension, tachycardia, and possibly cardiotoxicity. Droperidol: Moderate Scopolamine may cause dizziness and drowsiness. Edrophonium: Major The muscarinic actions of edrophonium chloride can antagonize the antimuscarinic actions of scopolamine.

Eluxadoline: Major Avoid use of eluxadoline with medications that may cause constipation, such as anticholinergics. Discontinue use of eluxadoline in patients who develop severe constipation lasting more than 4 days.

Erythromycin: Moderate Anticholinergics can antagonize the stimulatory effects of erythromycin on the GI tract when erythromycin is used therapeutically for improving GI motility. Avoid chronic administration of antimuscarinics along with prokinetic agents under most circumstances. Erythromycin; Sulfisoxazole: Moderate Anticholinergics can antagonize the stimulatory effects of erythromycin on the GI tract when erythromycin is used therapeutically for improving GI motility.

Esketamine: Moderate Closely monitor patients receiving esketamine and scopolamine for sedation and other CNS depressant effects. Instruct patients who receive a dose of esketamine not to drive or engage in other activities requiring alertness until the next day after a restful sleep. Ethanol: Moderate Scopolamine may cause dizziness and drowsiness. Ezogabine: Moderate Caution is advisable during concurrent use of ezogabine and medications that may affect voiding such as anticholinergic agents.

Ezogabine has caused urinary retention requiring catheterization in some cases. The anticholinergic effects of antimuscariinic and anticholinergic medications on the urinary tract may be additive. Additive sedation or other CNS effects may also occur. Fentanyl: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when fentanyl is used concomitantly with an anticholinergic drug.

Fluoxetine; Olanzapine: Moderate Olanzapine exhibits anticholinergic activity. Additive anticholinergic effects may be seen when olanzapine and anticholinergics are used concomitantly. Fluphenazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including fluphenazine.

Fluticasone; Umeclidinium; Vilanterol: Moderate There is the potential for umeclidinium to have additive anticholinergic effects when administered with other anticholinergics or antimuscarinics.

Per the manufaturer, avoid concomitant administration of umeclidinium with other anticholinergic medications when possible. Galantamine: Moderate The therapeutic benefits of galantamine, a cholinesterase inhibitor, may be diminished during chronic co-administration with antimuscarinics or medications with potent anticholinergic activity.

Glucagon: Major The concomitant use of intravenous glucagon and anticholinergics increases the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. Concomitant use is not recommended.

Glycopyrronium: Moderate Although glycopyrronium is minimally absorbed into the systemic circulation after topical application, there is the potential for glycopyrronium to have additive anticholinergic effects when administered with other antimuscarinics. Per the manufaturer, avoid concomitant administration of glycopyrronium with other anticholinergic medications. Guaifenesin; Hydrocodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug.

Guaifenesin; Hydrocodone; Pseudoephedrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Homatropine; Hydrocodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Hydrocodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug.

Hydrocodone; Ibuprofen: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug.

Hydrocodone; Phenylephrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug.

Hydrocodone; Potassium Guaiacolsulfonate: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug.

Hydrocodone; Pseudoephedrine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydrocodone is used concomitantly with an anticholinergic drug. Hydromorphone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when hydromorphone is used concomitantly with an anticholinergic drug. Hydroxyzine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.

Ibuprofen; Oxycodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when oxycodone is used concomitantly with an anticholinergic drug. Ipratropium: Moderate Although ipratropium is minimally absorbed into the systemic circulation after inhalation, there is the potential for additive anticholinergic effects when administered with other antimuscarinic or anticholinergic medications.

Itraconazole: Moderate Antimuscarinics can raise intragastric pH. This effect may decrease the oral bioavailability of itraconazole; antimuscarinics should be used cautiously in patients receiving itraconazole. Levodopa: Minor The doses of antimuscarinics and levodopa may need to be adjusted when the drugs are given simultaneously. Levorphanol: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when levorphanol is used concomitantly with an anticholinergic drug.

Linaclotide: Moderate Anticholinergics can promote constipation and pharmacodynamically oppose the action of drugs used for the treatment of constipation or constipation-associated irritable bowel syndrome, such as linaclotide.

Lofexidine: Moderate Monitor for excessive hypotension and sedation during coadministration of lofexidine and scopolamine. Lofexidine can potentiate the effects of CNS depressants. Loperamide: Moderate Loperamide decreases GI motility. Agents that inhibit intestinal motility or prolong intestinal transit time have been reported to induce toxic megacolon. Other drugs that also decrease GI motility may produce additive effects with loperamide if used concomitantly.

These include therapeutic doses of common systemic antimuscarinics e. Loxapine: Moderate Loxapine has anticholinergic activity. The concomitant use of loxapine and other anticholinergic drugs can increase the risk of anticholinergic adverse reactions including exacerbation of glaucoma, constipation, and urinary retention.

Lubiprostone: Moderate Antimuscarinic drugs can promote constipation and pharmacodynamically oppose the action of drugs used for the treatment of constipation, such as lubiprostone. The clinical significance of these potential interactions is uncertain. Lurasidone: Moderate Antipsychotic agents may disrupt core temperature regulation; therefore, caution is recommended during concurrent use of lurasidone and medications with anticholinergic activity such as antimuscarinics.

Concurrent use of lurasidone and medications with anticholinergic activity may contribute to heat-related disorders. Monitor patients for heat intolerance, decreased sweating, or increased body temperature if lurasidone is used with antimuscarinics.

Macimorelin: Major Avoid use of macimorelin with drugs that may blunt the growth hormone response to macimorelin, such as antimuscarinic anticholinergic agents. Healthcare providers are advised to discontinue anticholinergics at least 1 week before administering macimorelin.

Use of these medications together may impact the accuracy of the macimorelin growth hormone test. Magnesium Hydroxide: Moderate Antacids may inhibit the oral absorption of anticholinergics. Maprotiline: Moderate Additive anticholinergic effects may be seen when scopolamine is used concomitantly with other drugs with moderate to significant anticholinergic effects including maprotiline. Meclizine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.

Memantine: Moderate The adverse effects of anticholinergics, such as dry mouth, urinary hesitancy or blurred vision may be enhanced with use of memantine; dosage adjustments of the anticholinergic drug may be required when memantine is coadministered. Meperidine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when meperidine is used concomitantly with an anticholinergic drug. Meperidine; Promethazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including promethazine.

Moderate Monitor patients for signs of urinary retention or reduced gastric motility when meperidine is used concomitantly with an anticholinergic drug. Methacholine: Major Discontinue use of short-acting anticholinergics 12 hours before and long-acting anticholinergics hours or more before a methacholine challenge test. Anticholinergic drugs inhibit the airway response to methacholine.

Methadone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when methadone is used concomitantly with an anticholinergic drug. Metoclopramide: Moderate Drugs with significant antimuscarinic activity, such as anticholinergics and antimuscarinics, may slow GI motility and thus may reduce the prokinetic actions of metoclopramide.

Monitor patients for an increase in gastrointestinal complaints, such as reflux or constipation. Additive drowsiness may occur as well. The clinical significance is uncertain. Mirtazapine: Moderate Mirtazapine exhibits weak anticholinergic activity that is not expected to be clinically significant. However, the anticholinergic effects may be additive to the antimuscarinics.

Molindone: Moderate Antipsychotics are associated with anticholinergic effects; therefore, additive effects may be seen during concurrent use of molindone and other drugs having anticholinergic activity such as antimuscarinics. Additive drowsiness or other CNS effects may also occur. Morphine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when morphine is used concomitantly with an anticholinergic drug.

Morphine; Naltrexone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when morphine is used concomitantly with an anticholinergic drug.

Nabilone: Moderate Concurrent use of nabilone with anticholinergics may result in pronounced tachycardia and drowsiness. Nalbuphine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when nalbuphine is used concomitantly with an anticholinergic drug. Neostigmine: Major The muscarinic actions of neostigmine can antagonize the antimuscarinic actions of scopolamine. Nitrofurantoin: Moderate Antimuscarinics can delay gastric emptying, possibly increasing the bioavailability of nitrofurantoin.

Olanzapine: Moderate Olanzapine exhibits anticholinergic activity. Omeprazole; Sodium Bicarbonate: Moderate Antacids may inhibit the oral absorption of antimuscarinics. Orphenadrine: Moderate Additive anticholinergic effects may be seen when scopolamine is used concomitantly with other drugs with moderate to significant anticholinergic effects including orphenadrine. Oxycodone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when oxycodone is used concomitantly with an anticholinergic drug.

Oxymorphone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when oxymorphone is used concomitantly with an anticholinergic drug. Paroxetine: Moderate Of the selective serotonin reuptake inhibiting antidepressants SSRIs , paroxetine is considered the most anticholinergic. Additive anticholinergic effects may be seen when paroxetine is used concomitantly with anticholinergic agents. Additive drowsiness may also occur, depending on the specific anticholinergic used.

Pentazocine: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when pentazocine is used concomitantly with an anticholinergic drug.

Pentazocine; Naloxone: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when pentazocine is used concomitantly with an anticholinergic drug.

Perphenazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including perphenazine. Perphenazine; Amitriptyline: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including perphenazine.

Phentermine; Topiramate: Moderate Use caution if carbonic anhydrase inhibitors are administered with anticholinergics and monitor for excessive anticholinergic adverse effects.

Phenylephrine; Promethazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including promethazine. Physostigmine: Major The muscarinic actions of physostigmine can antagonize the antimuscarinic actions of scopolamine. Potassium: Major Drugs that decrease GI motility may increase the risk of GI irritation from sustained-release solid oral dosage forms of potassium salts. The use of solid oral dosage forms of potassium chloride is contraindicated in patients taking glycopyrrolate oral solution.

In one study, healthy subjects were examined for GI irritation following the administration of oral potassium for at least 7 days. Glycopyrrolate was coadministered to some subjects in order to study the additional effects of delayed gastric emptying.

Therefore, if oral potassium supplementation is necessary in a patient taking antimuscarinics, a liquid formulation should be considered. If a solid formulation is being prescribed, the patient should be counseled on strategies that can be used to avoid GI irritation such as taking potassium products only while seated or standing, remaining upright for 10 minutes after each dose, and ingesting each dose with plenty of fluids. Pramlintide: Major Pramlintide therapy should not be considered in patients taking medications that alter gastric motility, such as anticholinergics.

Pramlintide slows gastric emptying and the rate of nutrient delivery to the small intestine. Medications that have depressive effects on GI could potentiate the actions of pramlintide. Procainamide: Moderate The anticholinergic effects of procainamide may be significant and may be enhanced when combined with anticholinergics.

Anticholinergic agents administered concurrently with procainamide may produce additive antivagal effects on AV nodal conduction, although this is not as well documented for procainamide as for quinidine.

Prochlorperazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including prochlorperazine. Promethazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including promethazine. Proton pump inhibitors: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e.

Pyridostigmine: Major The muscarinic actions of pyridostigmine can antagonize the antimuscarinic actions of scopolamine. Quetiapine: Moderate When administering systemic anticholinergics and quetiapine together, monitor for additive anticholinergic effects such as constipation, blurred vision, urinary retention, xerostomia, and tachycardia.

Constipation is a commonly reported adverse effect of quetiapine and anticholinergic agents. Constipation in some cases may lead to ileus. Intestinal obstruction has been reported with quetiapine, including fatal cases in patients who were receiving multiple concomitant medications that decrease intestinal motility. Anticholinergic effects observed during therapeutic use of quetiapine are thought to be associated with norquetiapine, the active metabolite of quetiapine which has demonstrated a moderate to strong in vitro affinity for several muscarinic receptor subtypes.

Quinidine: Moderate The reduction in GI motility produced by scopolamine may increase the absorption of some drugs, including quinidine, resulting in increased anticholinergic effects. Additive anticholinergic effects may be seen when MAOIs are used concomitantly with antimuscarinics.

Remifentanil: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when remifentanil is used concomitantly with an anticholinergic drug. Revefenacin: Moderate Although revefenacin is minimally absorbed into the systemic circulation after inhalation, there is the potential for additive anticholinergic effects when administered with other antimuscarinics.

Avoid concomitant administration with other anticholinergic and antimucarinic medications. Rivastigmine: Moderate The therapeutic benefits of rivastigmine, a cholinesterase inhibitor, may be diminished during chronic co-administration with antimuscarinics or medications with potent anticholinergic activity.

Secretin: Major Discontinue anticholinergic medications at least 5 half-lives before administering secretin. Patients who are receiving anticholinergics at the time of stimulation testing may be hyporesponsive to secretin stimulation and produce a false result. Consider additional testing and clinical assessments for aid in diagnosis. Sedating H1-blockers: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics.

Sincalide: Moderate Sincalide-induced gallbladder ejection fraction may be affected by anticholinergics. False study results are possible in patients with drug-induced hyper- or hypo-responsiveness; thorough patient history is important in the interpretation of procedure results. Sodium Bicarbonate: Moderate Antacids may inhibit the oral absorption of antimuscarinics.

Solifenacin: Moderate Additive anticholinergic effects may be seen when drugs with antimuscarinic properties like solifenacin are used concomitantly with other antimuscarinics. Blurred vision and dry mouth would be common effects. Additive drowsiness may also occur. Sufentanil: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when sufentanil is used concomitantly with an anticholinergic drug.

Tacrine: Moderate The therapeutic benefits of tacrine, a cholinesterase inhibitor, may be diminished during chronic co-administration with antimuscarinics or medications with potent anticholinergic activity. Tapentadol: Moderate Tapentadol should be used cautiously with anticholinergic medications since additive depressive effects on GI motility or bladder function may occur.

Monitor patients for signs of urinary retention or reduced gastric motility. Opiate analgesics combined with antimuscarinics can cause severe constipation or paralytic ileus, especially with chronic use. Additive CNS effects like drowsiness or dizziness may also occur. Tegaserod: Major Drugs that exert significant anticholinergic properties such as antimuscarinics may pharmacodynamically oppose the effects of prokinetic agents such as tegaserod.

Avoid administering antimuscarinics along with tegaserod under most circumstances. Inhaled respiratory antimuscarinics, such as ipratropium, are unlikely to interact with tegaserod. Ophthalmic anticholinergics may interact if sufficient systemic absorption of the eye medication occurs. Thiazide diuretics: Minor Coadministration of thiazides and antimuscarinics e.

This is apparently a result of a decrease in gastrointestinal motility and rate of stomach emptying by the antimuscarinic agent.

In addition, diuretics can increase urinary frequency, which may aggravate bladder symptoms. Thioridazine: Moderate Additive anticholinergic effects may be seen when drugs with anticholinergic properties like thioridazine are used concomitantly with anticholinergic agents. Thiothixene: Moderate Anticholinergics may have additive effects with thiothixene, an antipsychotic with the potential for anticholinergic activity.

Monitor for anticholinergic-related adverse effects such as xerostomia, blurred vision, constipation, and urinary retention during concurrent use. Tiotropium: Moderate Although tiotropium is minimally absorbed into the systemic circulation after inhalation, tiotropium may have additive anticholinergic effects when administered with other antimuscarinics. Per the manufacturer, avoid concomitant administration of tiotropium with other anticholinergic medications when possible. Tiotropium; Olodaterol: Moderate Although tiotropium is minimally absorbed into the systemic circulation after inhalation, tiotropium may have additive anticholinergic effects when administered with other antimuscarinics.

Tolterodine: Moderate Additive anticholinergic effects may be seen when tolterodine is used concomitantly with other antimuscarinics. When possible, avoid concurrent use, especially in the elderly, who are more susceptible to the anticholinergic effects. Consider alternatives to these other medications, if available. Clinicians should note that antimuscarinic effects might be seen not only on bladder smooth muscle, but also on GI function, the eye, and temperature regulation.

Blurred vision, constipation, and dry mouth may be more prominent additive effects. With many of the listed agents, additive drowsiness may also occur when combined. Topiramate: Moderate Use caution if carbonic anhydrase inhibitors are administered with anticholinergics and monitor for excessive anticholinergic adverse effects. Tramadol: Moderate Monitor patients for signs of urinary retention or reduced gastric motility when tramadol is used concomitantly with an anticholinergic drug.

Tricyclic antidepressants: Moderate Depending on the specific agent, additive anticholinergic effects may be seen when tricyclic antidepressants TCAs are used concomitantly with other anticholinergics. Additive CNS effects are also possible when many of these drugs are combined with tricyclic antidepressants. Trifluoperazine: Moderate Additive anticholinergic effects may be seen when anticholinergics are used concomitantly with phenothiazines, including trifluoperazine.

The concurrent use of trimethobenzamide with other medications that cause CNS depression, like the anticholinergics, may potentiate the effects of either trimethobenzamide or the anticholinergic. Triprolidine: Moderate The anticholinergic effects of sedating H1-blockers may be enhanced when combined with other antimuscarinics. Trospium: Moderate Additive anticholinergic effects may be seen when trospium is used concomitantly with other antimuscarinics. With many of the listed agents, additive drowsiness may also occur when combined with trospium.

Umeclidinium: Moderate There is the potential for umeclidinium to have additive anticholinergic effects when administered with other anticholinergics or antimuscarinics. Umeclidinium; Vilanterol: Moderate There is the potential for umeclidinium to have additive anticholinergic effects when administered with other anticholinergics or antimuscarinics. Zonisamide: Moderate Zonisamide use is associated with case reports of decreased sweating, hyperthermia, heat intolerance, or heat stroke and should be used with caution in combination with other drugs that may also predispose patients to heat-related disorders like anticholinergics.

Scopolamine antagonizes acetylcholine at muscarinic receptors e. Because scopolamine is a tertiary amine like atropine, it can cross into the CNS. As an antiemetic, scopolamine probably blocks neural pathways from the vestibular nuclei in the inner ear to the brain stem and from the reticular formation to the vomiting center. Because acetylcholine mediates impulses from the inner ear, scopolamine is an effective antiemetic in motion sickness.

High doses of scopolamine produce symptoms of antimuscarinic toxicity such as restlessness, disorientation, irritability, and hallucinations. Reduction of secretions occurs by competitive blockade of acetylcholine and other cholinergic stimuli at cholinergic receptor sites on salivary and bronchial glands.

Scopolamine is well absorbed after oral, transdermal, and intramuscular or subcutaneous administration and is also given intravenously.

After absorption, scopolamine is distributed throughout the body and crosses the placenta and the blood-brain barrier.

The metabolism of scopolamine is not completely known, but the drug is believed to be almost completely metabolized in the liver and excreted renally as metabolites. The elimination half-life is about 8 hours. PDR Search. Required field. Your Name Your name is required.

Recipient's Email Separate multiple email address with a comma Please enter valid email address Recipient's email is required. Thank you. Your email has been sent.

Jump to Section. Related Drug Information Drug Summary. Subcutaneous dosage. Transdermal dosage. For use in aspiration prophylaxis prior to anesthesia and intubation; for treatment of bradycardia during surgery.

Subcutaneous, Intravenous, or Intramuscular dosage. Children 1 to 12 years. Intramuscular, Intravenous, or Subcutaneous dosage. Adults, Adolescents, and Children 7 years and older. Children 3 to 6 years. Children 3 years and younger and Infants 6 months and older. For use as a sedative or tranquilizer for sedation induction. For the adjunct treatment of alcohol withdrawal i.

Intravenous, Intramuscular, or Subcutaneous Dosage. Children greater than 5 years and weighing more than 15 kg. Intravenous Administration. Intramuscular Administration.

Subcutaneous Administration. Closed-angle glaucoma, contact lenses, open-angle glaucoma. Bladder obstruction, prostatic hypertrophy, urinary tract obstruction. Gastroesophageal reflux disease GERD , GI obstruction, hiatal hernia, ileus, laboratory test interference, pyloric stenosis, toxic megacolon, ulcerative colitis. Asthma, chronic obstructive pulmonary disease COPD. Cardiac arrhythmias, coronary artery disease, heart failure, hypertension, hyperthyroidism, tachycardia.

However, elderly patients are more likely to have age-related liver or kidney problems, which may require caution in patients receiving scopolamine transdermal patch. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur.

In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive. Using this medicine with any of the following medicines is not recommended.

Your doctor may decide not to treat you with this medication or change some of the other medicines you take. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur.

Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco. The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:. There is a problem with information submitted for this request.

Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID, plus expertise on managing health. Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information.

If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.